Published online: 2020-09-03 Commentary 831 Pulmonary Megakaryocytes in Coronavirus Disease 2019 (COVID-19): Roles in Thrombi and Fibrosis Jecko Thachil, MD, FRCP1 Ton Lisman, PhD2 1 Department of Haematology, Manchester Royal Infirmary, Address for correspondence Jecko Thachil, MD, FRCP, Department of Manchester, United Kingdom Haematology, Manchester Royal Infirmary, Oxford Road, Manchester 2 Surgical Research Laboratory and Section of Hepatobiliary Surgery M13 9WL, United Kingdom (e-mail: [email protected]). and Liver Transplantation, Department of Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands Semin Thromb Hemost 2020;46:831–834. Coronavirus disease 2019 (COVID-19) has already claimed karyocyte presence in the lungs assert that lung megakaryo- many lives and continues to do so in different parts of the cytes just represent a gravity phenomenon noted at autopsy. world. Autopsy reports of patients who succumbed to this viral The mostelegant (and latest)study for validating thelungorigin infection have been published despite concerns about health of platelets comes from Lefrançais et al who directly imaged the care professional safety. One of the unusual findings in COVID- lung microcirculation in mice to provide definite proof for the 19 lung autopsy reports is the increase in pulmonary mega- existence of lung megakaryocytes.8 They also proved that karyocytes.1,2 Although the presence of megakaryocytes in the approximately halfof the total number of platelets or 10 million lungs is a well-established concept in the medical literature, it platelets per hour would be produced by these cells.8 is still not widely accepted in the clinical fraternity. In this article, we discuss the role of lung megakaryocytes in relation fi fi Is There a Speci c Role for the Pulmonary to the clinicopathological ndings in COVID-19 and discuss Megakaryocytes? how this may impact on our understanding of acute respirato- ry distress syndrome (ARDS), pulmonary thrombi, and lung Lungs are one of the commonest sites for pathogen invasion, fibrosis, in general. and respiratory compromise from infectious diseases is the commonestcause of mortalityworldwide. Evolutionhasfor this fi Do Megakaryocytes Exist in the Lungs? reason prepared the human lungs with suf cient armamentar- ium to deal with the constant pathogen invasion, which hap- Platelets are produced from megakaryocytes by the process of pens with each breath of air we take. Since platelets are one of pseudopod formation.3 During this process, megakaryocyte the most abundant antiseptic cells available, it makes sensefor a cytoplasm elongates to form pseudopods, and the tips of these large number of platelets to be released in the vicinity of structures, which contain the characteristic granular constitu- possible pathogen entry (i.e., the alveolar–vascular interface). ents, get broken off in the vascular milieu to become platelets.3 In this respect, Lefrançais et al showed that the lung megakar- Although the assumption is that this production process occurs yocytes behave differently totheir marrowcounterparts.8 These in the bone marrow perisinusoidal region, there is evidence researchers used RNA sequencing analysis to demonstrate an that at least part of the production occurs in the lungs.4 innate immunity function for lung megakaryocytes in compar- Interestingly, the presence of lung megakaryocytes was noted ison with megakaryocytes from the bone marrow, with alter- more than six decades ago.5 There have even been studies that ations identifiable in cases of bacterial pneumonia.8 This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. demonstrate the megakaryocytes entering the marrow sinus- Nonhematopoietic roles of megakaryocytes also involve surface oids and traveling in the circulation to become lodged in tiny expression of toll-like receptors.9 Surface adhesion molecules capillaries of the pulmonary vasculature.6 Lungs as represent- expressed on megakaryocytes can assist in retention of these ing a factory for platelet production has been depicted by cells in the lungs, particularly when the pulmonary endotheli- human experiments showing higher platelet counts in the um is activated by inflammation or infection.10 Megakaryo- pulmonary arterial circulation compared with the venous cytes also phagocytose bacteria and viruses and use their – side.7 Despite these facts, proponents arguing against mega- lysosomal granules as pathogen-eradicating bullets.10 12 An published online Issue Theme Maintaining Hemostasis Copyright © 2020 by Thieme Medical DOI https://doi.org/ September 3, 2020 and Preventing Thrombosis in COVID-19 Publishers, Inc., 333 Seventh Avenue, 10.1055/s-0040-1714274. —Part I; Guest Editors: Emmanuel J. New York, NY 10001, USA. ISSN 0094-6176. Favaloro, PhD, FFSc (RCPA), and Giuseppi Tel: +1(212) 760-0888. Lippi, MD. 832 Pulmonary Megakaryocytes in COVID-19 Thachil, Lisman additional immune rolefor megakaryocytes is reflected by their karyocyte fragmentation and may also be a reason for throm- interaction with neutrophils, which occurs through the unique bocytopenia commonly noted in ARDS.22 There have been process called “emperipolesis.”13 During emperipolesis, these several publications detailing the role of platelets in ARDS, leukocytes are engulfed by the megakaryocytes with no mem- although very few in relation to megakaryocytes.23,24 This is brane disruption but allowing cellular material transfer be- possibly dueto thelackofawareness of the circulating andlung- tween the cells.13 Although not shown specifically with specific megakaryocytes and also the fact that “sourcing” these megakaryocytes in the lung fields, in response to acute inflam- large cells (50–100 μm in diameter, which are more than 10 mation, megakaryocytes become activated and manufacture times the size of typical red cells) through venepuncture large quantities of platelets, which can then play a role in needles would not be practical. One of these overlooked roles inflammatory conditions.14 In the context of COVID-19, throm- is in relation to platelet granular constituents including vaso- bocytosis has been observed as part of the inflammatory constrictors such as serotonin, which have been implicated in response, with very few patients having subnormal platelet the pathogenesis of ARDS.24 However, these granular constit- count pointing toward this very active megakaryocyte uents are also present inside megakaryocytes and as such their function.15 exact origin can be debated. Similarly, much interest has been shown in the interaction between platelets and the now well- 23 Lung Megakaryocytes and Pulmonary known neutrophil extracellular traps (NETs). However, Fryd- Thrombi man et al have shown that megakaryocytes can generate histone-decorated chromatin webs, which mimics the Microthrombi are a feature of many pulmonary diseases NETs.10 This report also demonstrated increased CD61þ stain- where there may be associated inflammation. It has been ing in the kidneys and lungs from patients with sepsis, which suggested that these clots assist in preventing microbes (in correlated with the development of organ dysfunction, an the case of infection) or damage-associated proteins (in the accompaniment often present in ARDS. case of inflammation) by escaping into the blood circulation and causing systemic effects, which may be harmful to the Megakaryocytes and Neovascularization host.16 Platelets are, of course, important in this micro- thrombi formation, and having the platelet production fac- One of the groundbreaking papers in the field of hemostatic tory to churn out a large amount of these cells locally in the factors in tumor angiogenesis is the discovery of differential lungs may indeed be beneficial.17 An intriguing observation release of angiogenesis mediators by the Battinelli et al.25 in this regard was made by Sharma and Talbot, who postu- These were experiments using platelets and not megakaryo- lated pulmonary megakaryocytes as the “missing link” be- cytes. They elegantly demonstrated that adenosine diphos- tween cardiovascular and respiratory disease.18 They phate stimulation of platelets triggered the release of vascular suggested that the number of pulmonary megakaryocytes endothelial growth factor (VEGF), whereas thromboxane A2 increased in association with atherosclerotic disease because stimulation released endostatin and not VEGF.25 The former of enhanced thrombopoiesis following increased platelet condition facilitated in vitro formation of capillary structures adherence to atheromatous plaques.18 Increase in lung meg- by human umbilical vein endothelial cells, whereas endostatin akaryocytes has been linked to pulmonary and cardiovascu- inhibited the same process.25 Neoangiogenesis is a feature lar disease and suggested to be a reason for preponderance of noted in COVID-19 lung pathology specimens and could be these diseases in men.18,19 Wells et al noted a significant induced by the vasogenic factors released by the activated correlation between the lung megakaryocytes and fibrin platelets produced by the lung megakaryocytes.26 But how can thrombi counts within the lungs in patients dying from we link megakaryocytes and neovascularization? It may be burns.20 The authors went far enough to postulate that any useful to recall the clinical sign of digital clubbing (bulbous condition that may cause disseminated intravascular coagu- enlargement of the tips of fingers or toes with sponginess of lation could be